Team:Chiba/Safety

Basic Safety Questions for iGEM 2013
Q1. Please describe the chassis organism(s) you will be using for this project. If you will be using more than one chassis organism, provide information on each of them:
Species Strain no/name Risk Group 2 3 4 5 6 7

Q2. Highest Risk Group Listed:

Ans. 1

Q3. List and describe all new or modified coding regions you will be using in your project. (If you use parts from the 2013 iGEM Distribution without modifying them, you do not need to list those parts.)

Ans.

	Part number	Where did you get the physical DNA for this part (which lab, synthesis company, etc	What species does this part originally come from?	What is the Risk Group of the species?	What is the function of this part, in its parent species?
1	BBa_K1057001	BBa_1746908	Aequorea victoria	1	Fluorescent protein(super folder GFP)
2	BBa_K1057002	Synthesized, DNA 2.0	Homo sapiens	1	Iron storange container proteins(2 orfs)
3	BBa_K1057003	Synthesized, DNA 2.0	Homo sapiens	1	Aid ferritin to store irons(chaperon)
4	BBa_K1057004	Synthesized, DNA 2.0	Homo sapiens	1	Three proteins coding for iron storage proteins and Fe chaperon
5	BBa_K1057005	Purchased from Addgene	Streptococcus pyogenes	2	Cas9 protein (exponuclease; useas CRISPi regulator protein)
6	BBa_K1057006	Modification from the material purchased from Addgene	Streptococcus pyogenes(partially)	2	sgRNA targeting to Fe uptake regulator fur and exportor fiefF in E. coli)
7	BBa_K1057007	Modification from the material purchased from Addgene	Streptococcus pyogenes(partially)	2	sgRNA targeting thioredoxin reductase in E.coli
8	BBa_K1057008	Modification from the material purchased from Addgene	Streptococcus pyogenes(partially)	2	sgRNA targeting glutathione reductase in E.coli

Q4. Do the biological materials used in your lab work pose any of the following risks? Please describe.

a. Risks to the safety and health of team members or others working in the lab?
Ans. No risk. Genes and modification version used in this project are half from human and are no reported toxicity to human being or other living system.

b. Risks to the safety and health of the general public, if released by design or by accident?
Ans. None.

c. Risks to the environment, if released by design or by accident?
Ans. None.

d. Risks to security through malicious misuse by individuals, groups, or countries?
Ans. None. To remove genes and organisms used in this project from our lab is restricted. In addition, we control them not to be taken out by other people.

Q5. If your project moved from a small-scale lab study to become widely used as a commercial/industrial product, what new risks might arise? (Consider the different categories of risks that are listed in parts a-d of the previous question.) Also, what risks might arise if the knowledge you generate or the methods you develop became widely available? (Note: This is meant to be a somewhat open-ended discussion question.)

Ans. Production and dispersion of amount of ferritin could result in the decrease from environment.　Moreover, because this project use iron solution, if this project is carried out in large scale, huge amount of iron solution occurs and they probably pollute environment.

Q6. Does your project include any design features to address safety risks? (For example: kill switches, auxotrophic chassis, etc.) Note that including such features is not mandatory to participate in iGEM, but many groups choose to include them.

Ans. No. Due to the nature of the DNA we use in this project, we did not find need for safety devices such as kill-swithces (spontaneous mutations anyway kill off the suicide devices…)

Q7. What safety training have you received (or plan to receive in the future)? Provide a brief description, and a link to your institution’s safety training requirements, if available.

Ans.1. Official seminars on recombinant DNA and its biosafety rules in Japan.
Ans.2. Special lectures and coaching held by our mentors, Prof. Daisuke Umeno and Prof. Shigeko Kawai.

Q8. Under what biosafety provisions will / do you work?

a. Please provide a link to your institution biosafety guidelines.
http://www.jm.chiba-u.jp/kenkyu/005/newpage1.htm

b. Does your institution have an Institutional Biosafety Committee, or an equivalent group? If yes, have you discussed your project with them? Describe any concerns they raised with your project, and any changes you made to your project plan based on their review.

Ans. Yes. One of our mentors, Prof. Daisuke Umeno, is the board member of the Chiba University Biosafety Committee.

c. Does your country have national biosafety regulations or guidelines? If so, please provide a link to these regulations or guidelines if possible.

Ministry Education:http://www.bch.biodic.go.jp/bioethics/anzen.html
Ministry Environment:http://www.lifescience.mext.go.jp/english/e_index.html

d. According to the WHO Biosafety Manual, what is the BioSafety Level rating of your lab? (Check the summary table on page 3, and the fuller description that starts on page 9.) If your lab does not fit neatly into category 1, 2, 3, or 4, please describe its safety features.

Ans. BSL2

e. What is the Risk Group of your chassis organism(s), as you stated in question 1? If it does not match the BSL rating of your laboratory, please explain what additional safety measures you are taking.

Ans. We use Saccharomyces cerevisiae(BSL1) and E.coli(K-12,BSL1), only and the place of experiment(Umeno lab, BSL2) is suitable manipulating them.

Faculty Advisor Name: Daisuke Umeno